What pharmacologic agents are used to close a patent ductus arteriosus (PDA)?

PDA Closure Drugs

For pharmacologic closure of patent ductus arteriosus in neonates, use ibuprofen as first-line therapy, with indomethacin or acetaminophen (paracetamol) as alternatives.

Primary Pharmacologic Agents

The three main drugs used for PDA closure are:

Ibuprofen (First-Line)

• Preferred agent due to superior safety profile 1, 2
• Closure rate: 63-70% after initial course 3, 4, 1
• Significantly fewer adverse effects compared to indomethacin, specifically:
  • Lower risk of intraventricular hemorrhage (IVH)
  • Reduced oliguria/renal dysfunction 1
  • Fewer gastrointestinal complications 2
• Available as ibuprofen lysine or ibuprofen arginine formulations (both equally effective) 3
• Oral administration may be more effective than IV due to pharmacokinetics 2

Indomethacin (Alternative)

• Closure rate: 71.5% after initial course 4, 1
• Comparable efficacy to ibuprofen for ductal closure 1
• Higher risk of adverse effects:
  • 27% increased risk of IVH compared to ibuprofen 1
  • 3.9-fold higher risk of oliguria versus ibuprofen 1
  • More gastrointestinal and renal side effects 2
• Reserve for cases where ibuprofen is contraindicated or unavailable

Acetaminophen/Paracetamol (Emerging Alternative)

• Closure rate: 70% after initial course 4, 1
• Non-inferior efficacy to both ibuprofen and indomethacin 4
• Lowest adverse event profile among all three agents 1, 2
• Most cost-effective option: $1,487 per successful closure vs. $2,585 (ibuprofen) and $2,661 (indomethacin) 4
• 10.8-fold lower risk of oliguria compared to indomethacin 1
• Typical dosing: 15 mg/kg orally every 6 hours 5
• Achieves closure within 48 hours in most cases 5
• Consider as first-line when cyclooxygenase inhibitors are contraindicated 5

Mechanism of Action

All three agents work as cyclooxygenase inhibitors (ibuprofen and indomethacin) or through alternative prostaglandin pathways (acetaminophen), blocking prostaglandin conversion from arachidonic acid, which maintains ductal patency 2, 6.

Clinical Algorithm

1. First attempt: Ibuprofen (lysine or arginine formulation)
2. If contraindicated or failed: Acetaminophen
3. If both unavailable/failed: Indomethacin
4. If pharmacologic therapy fails: Consider repeat course (needed in 35-54% of cases) 3 or surgical/transcatheter closure 7

Critical Caveats

• All three drugs have comparable closure rates (63-71%), so choice should be based primarily on safety profile 3, 4, 1
• Pharmacologic therapy is inversely associated with need for surgical closure compared to no treatment (OR 0.17-0.30) 1
• Monitor for adverse effects: transient renal failure, gastrointestinal bleeding/perforation, hyperbilirubinemia, platelet dysfunction 2
• Important limitation: Current evidence shows ductal closure alone does not consistently improve long-term neurodevelopmental outcomes 8
• Treatment decisions should focus on hemodynamically significant PDA rather than anatomical presence alone 8

Note on Adult PDA

The provided guidelines 9, 10 address adult congenital heart disease and recommend percutaneous device closure or surgical intervention rather than pharmacologic therapy, as medications are ineffective for established PDA in adults.